Fig. 6.

The inhibitory effect of CHPV on the eGFP-ZEBOV infection. The final treatment concentrations of CHPV were 2-fold dilutions beginning with 100 μg/ml down to 0.78 μg/ml, and 2G4 was started with 2.5 μg/ml followed by 2-fold dilutions down to 0.020 μg/ml. The indicated concentrations of CHPV or MAb alone were added to VeroE6 cells (A) or different concentrations of CHPV or MAb were mixed (as indicated) and added to VeroE6 cells (B) before exposure of the cells to 100 PFU of eGFP-ZEBOV. After incubating for12 h, the medium was changed with fresh medium. At 48 h later, cells were fixed with 10% phosphate-buffered formalin and fluorescent plaques were counted using an AID fluorescent plate reader. Error bars represent variation between triplicate samples, and the data of (A) and (B) are representative of results obtained in two independent experiments.